BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:17 PM
 | 
Oct 01, 2008
 |  BC Extra  |  Company News

OxiGene, Symphony in cancer, ophthalmic deal

OxiGene (NASDAQ:OXGN; SSE:OXGN) out-licensed Zybrestat fosbretabulin for ophthalmic indications and OXi4503 to Symphony ViDA. Symphony ViDA was formed by Symphony Capital, which provided an initial investment of $15 million and agreed to provide up to an additional $10 million in the first two years of the collaboration....

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >